Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.72 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | NPY1R | P25929 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | NPY2R | P49146 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14946390 | 1.00 | ADORA3 (0.72) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL20801120 | 1.00 | ADORA3 (0.72) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL3164693 | 1.00 | ADORA3 (0.72) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL17234118 | 1.00 | ADORA3 (0.72) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL8425718 | 1.00 | ADORA3 (0.72) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL14929512 | 1.00 | ADORA3 (0.72) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL23647923 | 1.00 | ADORA3 (0.72) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL40634 | 1.00 | ADORA3 (0.72) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL25100667 | 0.99 | ADORA3 (0.71) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| Trimethylammonium SCHEMBL27839944 | 0.97 | ADORA3 (0.68) | ADORA3SLC29A1LMNAALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14982 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4747386-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE AGENTS AND USES THEREOF | Bisirna Therapeutics Pte. Ltd. (SG) | 2026-05-27 | — | — | EP | claimed |
| CN-122095092-A | Inhibitor for inhibiting inhibin Beta E gene expression and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026107352-A1 | COMPOSITIONS AND METHODS FOR EFFICIENT NUCLEIC ACID ASSEMBLY AND TISSUE ENGINEERING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026103936-A1 | CHEMICALLY MODIFIED CIRCULAR RNA MOLECULE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海元码智药生物技术有限公司 | 2026-05-21 | — | — | WO | claimed |
| CN-122060818-A | Chemically modified circular RNA molecules, methods of making and uses thereof | 上海元码智药生物技术有限公司 | 2026-05-19 | — | — | CN | claimed |
| EP-4739343-A2 | CIRCULAR RNA VACCINES FOR SEASONAL FLU AND METHODS OF USES | Shanghai Circode Biomed Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| CN-122005867-A | Use of a substance that increases IRF5 content in a subject in a product of pulmonary fibrosis | 广州国家实验室 | 2026-05-12 | — | — | CN | claimed |
| CN-122005811-A | Application of IGF2BP2-m6A-VCAN-TLR2 signal shaft in preparation of medicine for treating intrahepatic bile duct cancer lymphatic metastasis | 温州医科大学附属第一医院 | 2026-05-12 | — | — | CN | claimed |
| EP-1226238-A2 | METHOD FOR CREATING DIVERGENT POPULATIONS OF NUCLEIC ACID MOLECULES AND PROTEINS | Cytos Biotechnology AG (CH) | 2002-07-31 | — | — | EP | claimed |
| WO-2001078709-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| WO-2001030989-A2 | METHOD FOR CREATING DIVERGENT POPULATIONS OF NUCLEIC ACID MOLECULES AND PROTEINS | CYTOS BIOTECHNOLOGY AG (US) | 2001-05-03 | — | — | WO | claimed |
| EP-0661291-B1 | Solid phase synthesis of oligoribonucleotide | AVENTIS PHARMA GMBH (DE) | 2001-03-07 | — | — | EP | claimed |
| EP-0795029-A1 | CHEMICAL LABELLING OF OBJECTS | Pabio (NO) | 1997-09-17 | — | — | EP | claimed |
| US-5652358-A | Solid-phase synthesis of oligoribonucleotides | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-07-29 | — | — | US | claimed |
| EP-0770144-A1 | NUCLEIC ACID AMPLIFICATION METHOD USING A MODIFIED NUCLEOSIDE, AND DETECTION OF THE AMPLIFICATION PRODUCT USING ANTIBODIES | PARTEUROP DEVELOPPEMENT (FR) | 1997-05-02 | — | — | EP | claimed |
| WO-1996017954-A1 | CHEMICAL LABELLING OF OBJECTS | PABIO (DK) | 1996-06-13 | — | — | WO | claimed |
| WO-1996003526-A1 | NUCLEIC ACID AMPLIFICATION METHOD USING A MODIFIED NUCLEOSIDE, AND DETECTION OF THE AMPLIFICATION PRODUCT USING ANTIBODIES | PARTEUROP DEVELOPPEMENT (FR) | 1996-02-08 | — | — | WO | claimed |
| EP-0661291-A1 | Solid phase synthesis of oligoribonucleotide | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-07-05 | — | — | EP | claimed |